384
Participants
Start Date
October 31, 2007
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
Ixabepilone
Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
Paclitaxel
Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
Cyclophosphamide
Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
Doxorubicin
Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
Local Institution, Callao
Local Institution, Lima
Local Institution, Taipei
Local Institution, Vienna
Local Institution, Quezon City
Local Institution, Capital Federal
Local Institution, Capital Federal
Local Institution, Buenos Aires
Local Institution, Salzburg
Local Institution, Cebu City
Local Institution, Davao City
Albert Einstein Cancer Center, The Bronx
Local Institution, Taipei
Local Institution, Jaén
Local Institution, Lleida
Local Institution, Bordeaux
Northwest Oncology & Hematology Associates, Coral Spring
Florida Cancer Research Institute, Davie
Medical Specialists Of Palm Beaches, Lake Worth
Moffitt Cancer Center, Tampa
Local Institution, Bologna
University Medical Center, Inc, Louisville
Local Institution, Düsseldorf
Local Institution, Saint-Herblain
University Of New Mexico Cancer Center, Albuquerque
Local Institution, Erlangen
Comprehensive Cancer Center, Palm Springs
Virginia Mason Medical Center, Seattle
Providence Cancer Center, Spokane
Local Institution, Moscow
Local Institution, Saint Petersburg
Local Institution, Singapore
Local Institution, Mumbai
Local Institution, Pune
Local Institution, Kazan'
Local Institution, Bhopal
Local Institution, Bangalore
Local Institution, Vellore
Local Institution, Trivandrum
Local Institution, Buenos Aires
Local Institution, Jena
Local Institution, New Delhi
Local Institution, Hyderabad
Local Institution, Lima
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Barcelona
Local Institution, Nottingham
Local Institution, Coventry
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY